Survodutide is a novel, long-acting peptide being developed for once-weekly subcutaneous administration.
It activates both the GLP‑1 receptor—to suppress appetite and improve glycemic control—and the glucagon receptor—to increase energy expenditure and potentially reduce liver fat.PMC+15zealandpharma.com+15PMC+15
In overweight or obese individuals without diabetes who received weekly doses—0.6, 2.4, 3.6, or 4.8 mg—for 46 weeks:
Weight loss ranged from –6.2% to –14.9%, correlating with increasing doses.pace-cme.org+2biomolther.org+2
At the highest dose (4.8 mg), 55% of participants lost at least 15% of body weight.pace-cme.org
Improvements were also observed in waist circumference (–12 cm), systolic blood pressure (–6.2 mmHg), and diastolic blood pressure.DrugBank+15pace-cme.org+15PMC+15
Gastrointestinal side effects were the most common cause of treatment discontinuation (25% vs. 4% placebo), though serious adverse events were less frequent than in the placebo group.diaTribe+3pace-cme.org+3PMC+3
In individuals with MASH (fatty liver disease), survodutide significantly improved liver health:
83% of patients showed histological improvement in liver fibrosis after ~48 weeks.Synapse+15Boehringer Ingelheim+15Oxford Online Pharmacy+15Financial Times
It’s now being tested in several Phase 3 trials (SYNCHRONIZE‑1 and ‑2 for people with and without type 2 diabetes, respectively), as well as cardiovascular outcomes trials and trials in Asian populations.zealandpharma.com+2PMC+2
Regulatory status: Survodutide has received FDA Fast Track and Breakthrough Therapy designations, as well as EMA PRIME status for MASH.PubMed+10zealandpharma.com+10Boehringer Ingelheim+10
Projected launch timeline: If trials remain positive, Boehringer Ingelheim aims for a 2027–2028 approval, potentially first in areas like obesity or MASH.reuters.com+4reuters.com+4Oxford Online Pharmacy+4
Survodutide is a novel, long-acting peptide being developed for once-weekly subcutaneous administration.
It activates both the GLP‑1 receptor—to suppress appetite and improve glycemic control—and the glucagon receptor—to increase energy expenditure and potentially reduce liver fat.PMC+15zealandpharma.com+15PMC+15
In overweight or obese individuals without diabetes who received weekly doses—0.6, 2.4, 3.6, or 4.8 mg—for 46 weeks:
Weight loss ranged from –6.2% to –14.9%, correlating with increasing doses.pace-cme.org+2biomolther.org+2
At the highest dose (4.8 mg), 55% of participants lost at least 15% of body weight.pace-cme.org
Improvements were also observed in waist circumference (–12 cm), systolic blood pressure (–6.2 mmHg), and diastolic blood pressure.DrugBank+15pace-cme.org+15PMC+15
Gastrointestinal side effects were the most common cause of treatment discontinuation (25% vs. 4% placebo), though serious adverse events were less frequent than in the placebo group.diaTribe+3pace-cme.org+3PMC+3
In individuals with MASH (fatty liver disease), survodutide significantly improved liver health:
83% of patients showed histological improvement in liver fibrosis after ~48 weeks.Synapse+15Boehringer Ingelheim+15Oxford Online Pharmacy+15Financial Times
It’s now being tested in several Phase 3 trials (SYNCHRONIZE‑1 and ‑2 for people with and without type 2 diabetes, respectively), as well as cardiovascular outcomes trials and trials in Asian populations.zealandpharma.com+2PMC+2
Regulatory status: Survodutide has received FDA Fast Track and Breakthrough Therapy designations, as well as EMA PRIME status for MASH.PubMed+10zealandpharma.com+10Boehringer Ingelheim+10
Projected launch timeline: If trials remain positive, Boehringer Ingelheim aims for a 2027–2028 approval, potentially first in areas like obesity or MASH.reuters.com+4reuters.com+4Oxford Online Pharmacy+4
